# A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

> **NCT01042028** · PHASE1,PHASE2 · TERMINATED · sponsor: **Per Pfeiffer** · enrollment: 39 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Everolimus, Cetuximab, Irinotecan
- **DRUG:** Capecitabine, Oxaliplatine

## Key facts

- **NCT ID:** NCT01042028
- **Lead sponsor:** Per Pfeiffer
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2012-11
- **Final completion:** 2014-01
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Emergence of FOLFIRINOX and slow recruitment
- **Last updated:** 2015-10-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01042028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01042028, "A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01042028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*